Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.66 USD

12.66
254,121

+0.02 (0.16%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $12.68 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4

by Zacks Equity Research

Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.

    Zacks Equity Research

    Corcept's (CORT) Earnings and Sales Meet Estimates in Q4

    by Zacks Equity Research

    Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.

      Zacks Equity Research

      AbbVie Presents New Data on Upadacitinib for Crohn's Disease

      by Zacks Equity Research

      AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

        Zacks Equity Research

        Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

        by Zacks Equity Research

        Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

          Zacks Equity Research

          Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

          by Zacks Equity Research

          Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

            Zacks Equity Research

            AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

            by Zacks Equity Research

            AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

              Zacks Equity Research

              Will Conatus Liver Disease Candidate Drive Long-Term Growth?

              by Zacks Equity Research

              Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.

                Zacks Equity Research

                Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session

                by Zacks Equity Research

                Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.

                  Zacks Equity Research

                  Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)

                  by Zacks Equity Research

                  Enanta Pharmaceuticals (ENTA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                    Zacks Equity Research

                    Will Conatus Key Candidate Emricasan Drive Long-Term Growth?

                    by Zacks Equity Research

                    Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.